edoc

Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era : evaluation of its impact within a subgroup of the randomized German CML Study IV

Saussele, Susanne and Lauseker, Michael and Gratwohl, Alois and Beelen, Dietrich W. and Bunjes, Donald and Schwerdtfeger, Rainer and Kolb, Hans-Jochem and Ho Anthony, D. and Falge, Christiane and Holler, Ernst and Schlimok, Günter and Zander, Axel R. and Arnold, Renate and Kanz, Lothar and Dengler, Robert and Haferlach, Claudia and Schlegelberger, Brigitte and Pfirrmann, Markus and Müller, Martin C. and Schnittger, Susanne and Leitner, Armin and Pletsch, Nadine and Hochhaus, Andreas and Hasford, Joerg and Hehlmann, Rüdiger and German CML Study Group, . (2010) Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era : evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood, Vol. 115, H. 10. pp. 1880-1885.

Full text not available from this repository.

Official URL: http://edoc.unibas.ch/dok/A6006302

Downloads: Statistics Overview

Abstract

The role of allogeneic stem cell transplantation in chronic myeloid leukemia is being reevaluated. Whereas drug treatment has been shown to be superior in first-line treatment, data on allogeneic hematopoietic stem cell transplantation (allo SCT) as second-line therapy after imatinib failure are scarce. Using an interim safety analysis of the randomized German CML Study IV designed to optimize imatinib therapy by combination, dose escalation, and transplantation, we here report on 84 patients who underwent consecutive transplantation according to predefined criteria (low European Group for Blood and Marrow Transplantation [EBMT] score, imatinib failure, and advanced disease). Three-year survival after transplantation of 56 patients in chronic phase was 91% (median follow-up: 30 months). Transplantation-related mortality was 8%. In a matched pair comparison of patients who received a transplant and those who did not, survival was not different. Three-year survival after transplantation of 28 patients in advanced phase was 59%. Eighty-eight percent of patients who received a transplant achieved complete molecular remissions. We conclude that allo SCT could become the preferred second-line option after imatinib failure for suitable patients with a donor. The study is registered at the National Institutes of Health, http://clinicaltrials.gov: NCT00055874.
Faculties and Departments:03 Faculty of Medicine > Bereich Medizinische Fächer (Klinik) > Ehemalige Einheiten Medizinische Fächer (Klinik) > Hämatologie (Gratwohl)
03 Faculty of Medicine > Departement Klinische Forschung > Bereich Medizinische Fächer (Klinik) > Ehemalige Einheiten Medizinische Fächer (Klinik) > Hämatologie (Gratwohl)
UniBasel Contributors:Gratwohl, Alois A.
Item Type:Article, refereed
Article Subtype:Research Article
Bibsysno:Link to catalogue
Publisher:American Society of Hematology
ISSN:1528-0020
Note:Publication type according to Uni Basel Research Database: Journal article
Related URLs:
Identification Number:
Last Modified:01 Feb 2013 08:46
Deposited On:01 Feb 2013 08:42

Repository Staff Only: item control page